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BACKGROUND
The development of atypical (or second
generation) antipsychotics has offered
people with schizophrenia more treat-
ment options. Atypical antipsychotics
are judged to be more effective in allevi-
ating symptoms of the illness and to be
associated with fewer side-effects in
most patients. They are more expensive
than the earlier class of antipsychotics,
so-called typical antipsychotics, but
doubt remains as to whether or not they
are more cost-effective in treating
patients with schizophrenia.
Spending on antipsychotics in the
United Kingdom was ten times greater
in 2002 than it was in 1996, a trend
matched in much of Europe. The intro-
duction and uptake of atypical
antispychotics has been the primary rea-
son. And in July 2002, the National
Institute for Clinical Excellence (NICE)
published guidance favouring the use of
atypical antipsychotics as a first-line
treatment for patients with schizophre-
nia, which has contributed to an increase
in the rate of prescribing of atypicals rel-
ative to typicals and increased the propor-
tion of mental health drug spending that
goes towards prescribing antipsychotics.
THE STUDY
Using the General Practice Research
Database (GPRD) we assess changes in
the prescribing of atypical antipsychotics
in the treatment of schizophrenia and
schizoaffective disorder over time and
explore associations between individual
characteristics and the changes in pre-
scribing patterns.
The GPRD is a computerised database
of anonymised general practice patient
records. It began in 1987 and now con-
tains over 30 million patient years of
information. The database currently
collects information on approximately 3
million patients – approximately 4.7% of
the UK population – provided by a
cross-section of practices, drawn from
across the UK.
To assess the prescribing patterns of
atypical antipsychotics in the early part
of their availability, the study used data
from January 1993 through to Decem-
ber 1999. Atypical antipsychotic medi-
cations were not prescribed in the UK
before 1993 and problems with the
dataset that occurred in 2000 and 2001
resulted in a significantly reduced pool of
observations. Our analysis linked annual
GPRD datasets from one year to the next
for individual patients based on their
unique patient identification number.
Our sample includes every individual
who received at least one prescription
for an antipsychotic medication, who
was enrolled in the General Practice
Research Database for the entire year
and had been diagnosed with schizo-
phrenia or schizoaffective disorder prior
to the beginning of that year. There were
no other inclusion or exclusion criteria.
The individual patient characteristics
considered in our model of the prescrib-
ing choice over time were: age, sex,
number of years since schizophrenia or
schizoaffective disorder diagnosis,
whether or not they had been an inpa-
tient in the previous year and number of
GP visits in the previous year.
RESULTS
A total of 4,391 patients contributed
data to our analysis. Of the patients who
contributed data in 1993, 1.8% were
prescribed an atypical antipsychotic, but
by 1999, the rate had increased to 20.8%
(see Figure 1). This rate of growth is
comparable to UK data from other
sources, although none appear to have
looked at as wide a sample as we were
able to examine.
Data from the NHS Prescription Pricing
Authority indicates that the rate of atypi-
cal antipsychotic prescribing in General
Practice in England has increased sub-
stantially since the period observed in
our study, from 21.3% in June 2000 to
61.1% in June 2005. These data are not
strictly comparable to the GPRD data,
however, as they include prescribing for
indications other than schizophrenia and
schizoaffective disorder and relate to
rates in England only, as compared to
the GPRD which incorporates data for
all of the UK.
Our analysis identified three significant
correlates of prescription choice: age,
previous inpatient stay and previous fre-
quency of primary care consultation.
Older patients were less likely to be pre-
scribed an atypical as compared to a typ-
ical antipsychotic. And those who in the
last year had either an inpatient stay or a
high frequency of GP visits were more
likely to be prescribed an atypical as
compared to a typical antipsychotic.
Gender and time since first diagnosis of
schizophrenia or schizoaffective disorder
were not associated with higher or lower
odds of being prescribed an atypical
antipsychotic.
Age
A five-year increase in age was associ-
ated with a decrease by 15% in the
probability of being prescribed an atypi-
cal antipsychotic. So, for example, all
other things being equal, a 35 year old
would be 15% less likely to be pre-
scribed an atypical antipsychotic as com-
pared to a 30 year old. Possible
explanations for this effect are that (i)
younger patients in the sample, if newly
diagnosed, are more likely be prescribed
an atypical antipsychotics as their initial
prescription; (ii) GPs may be more
defensive in their prescribing to older
patients, due to initial warnings that
atypical antipsychotics increase the risk
of ischaemic stroke in older patients
(recent research has concluded no
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Figure 1 Per cent of patients
prescribed atypical
antipsychotics
significant difference exists in the risk of
ischaemic stroke for dementia patients
taking atypical antipsychotics as com-
pared to typical antipsychotics); or (iii)
older patients, having had their illness
for a longer period of time (the age of
onset of schizophrenia being almost
always in early adulthood), were more
likely to have been stabilised on a typical
antipsychotic and therefore less likely to
be prescribed an atypical antipsychotic
(however, a test of the effect of time
since diagnosis found this effect not
statistically significant).
Inpatient stays in the previous 12
months
Patients who had an inpatient stay in the
previous year were over one and a half
times as likely to receive atypical
antipsychotics as compared to a typical
antipsychotic. If it is reasonable to
assume that inpatient admission follows
an exacerbation of symptoms, then it
can be inferred that patients with more
severe illness, or whose illness has not
been stabilised, are more likely to be pre-
scribed atypical antipsychotics. Alterna-
tively, this result may reflect a preference
of prescribing atypical antipsychotics, for
acute patients, by hospital-based psychi-
atrists. The prescription choice would
then be continued by the patient’s GP
once they were discharged from hospital.
GP visits in the previous 12 months
Patients who had visited their GP six or
more times in the previous year were
over one and a half times as likely to
receive atypical antipsychotics as com-
pared to a typical antipsychotic. This
may reflect that patients presenting with
more complex needs were more likely to
be prescribed atypicals. Another possi-
bility is that a high number of GP visits
reflect problems with side-effects that
may induce a switch to an atypical
antipsychotic.
The setting of care may also be a key
factor in the prescription choice. Just as
hospital psychiatrists may prescribe
more atypical antipsychotics as they are
often treating acutely ill patients, GPs
may prefer using the older typical
antipsychotics as they are more likely to
be familiar with these drugs. As the
GPRD data are primary care-based,
there may be a bias in lower rates of
atypical antipsychotic prescribing in
these data.
SUMMARY
The trend of an increase in the rate of
atypical antipsychotic prescribing in
schizophrenia, as a percentage of all
antipsychotic prescribing, is likely to
continue. Reductions in their real prices,
relative to typical antipsychotics, seems
likely to encourage GPs to prescribe
atypical antipsychotics more frequently
in preference to the older medications.
The modelling results indicate that in
prescribing for patients with schizophre-
nia or schizoaffective disorder, it is the
case that factors not directly indicative
of need were being used by GPs in mak-
ing the choice between atypical and
typical antipsychotics.
This study is potentially limited by the
scope and content of the source of data.
The GPRD includes prescribing data on
prescribing initiated by the GP or by a
specialist in an outpatient setting. The
dataset does not include records of hos-
pital inpatient prescribing, which may
represent a sizeable proportion of
antipsychotic prescribing. Data from IMS
Health on sales of atypical antipsychotic
in the United Kingdom indicate that in
2002 approximately 33% of prescriptions
for atypical antipsychotics take place
within hospitals.
Ideally, we would also have included
more detailed data on the characteristics
of patients, and medical practitioners,
but these data were not available. It has
been suggested by other UK studies that
receipt of an atypical rather than a typi-
cal antipsychotic is linked to factors such
as treatment history, risk of non-adher-
ence and ethnicity.
The impact of the NICE guidance on
the rate of increase in atypical
antipsychotic prescribing and on the
transparency in the prescribing choice
are interesting issues for further
research. Additional analyses are also
necessary to determine whether or not
these trends are consistent across the
atypical class of antipsychotics.
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Box 1. Main findings
 In the General Practice Research Database, atypical antipsychotics as a percentage
of antipsychotic prescribing by GPs for schizophrenia and schizoaffective disorder
increased from 1.8% in 1993 to 20.8% in 1999.
 Older schizophrenia and schizoaffective disorder patients were significantly less
likely to be prescribed an atypical antipsychotic relative to a typical antipsychotic.
 Patients who had an inpatient stay in the previous year were significantly more
likely to be prescribed an atypical antipsychotic.
 Patients who had a high number of GP visits in the previous year were significantly
more likely to be prescribed an atypical antipsychotic.
 The prescribing choice made by GPs in treating patients with schizophrenia or
schizoaffective disorder was not made solely on needs-based criteria.
